Adverum Biotechnologies (ADVM) Competitors $2.54 -0.18 (-6.62%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.50 -0.04 (-1.77%) As of 07/11/2025 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. NLTX, PROK, ALMS, ELDN, CYBN, TIL, PBYI, VYGR, TLSA, and IMABShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Neoleukin Therapeutics (NLTX), ProKidney (PROK), Alumis (ALMS), Eledon Pharmaceuticals (ELDN), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Neoleukin Therapeutics ProKidney Alumis Eledon Pharmaceuticals Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences I-Mab Neoleukin Therapeutics (NASDAQ:NLTX) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Which has better valuation & earnings, NLTX or ADVM? Neoleukin Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.89Adverum Biotechnologies$1M53.06-$130.93M-$6.40-0.40 Which has more risk & volatility, NLTX or ADVM? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Do analysts recommend NLTX or ADVM? Adverum Biotechnologies has a consensus target price of $23.80, suggesting a potential upside of 837.01%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to NLTX or ADVM? In the previous week, Adverum Biotechnologies had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Adverum Biotechnologies and 0 mentions for Neoleukin Therapeutics. Adverum Biotechnologies' average media sentiment score of 1.89 beat Neoleukin Therapeutics' score of 0.00 indicating that Adverum Biotechnologies is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral Adverum Biotechnologies Very Positive Do insiders & institutionals have more ownership in NLTX or ADVM? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is NLTX or ADVM more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Adverum Biotechnologies N/A -130.53%-66.31% SummaryAdverum Biotechnologies beats Neoleukin Therapeutics on 8 of the 14 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.82M$2.96B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-0.4020.8528.1820.27Price / Sales53.06289.03428.7098.48Price / CashN/A42.8637.4658.16Price / Book0.757.638.045.49Net Income-$130.93M-$55.05M$3.19B$250.45M7 Day Performance6.50%8.43%3.62%4.79%1 Month Performance-1.93%5.42%4.06%7.68%1 Year Performance-67.89%2.03%30.00%16.43% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.5837 of 5 stars$2.54-6.6%$23.80+837.0%-67.4%$56.82M$1M-0.40190Positive NewsNLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-49.1%$188.81MN/A-6.4690PROKProKidney2.6633 of 5 stars$0.61-4.8%$3.50+477.1%+89.2%$186.51M$306K-1.013News CoverageAnalyst ForecastInsider TradeGap DownALMSAlumis3.5977 of 5 stars$3.31-2.6%$22.86+590.5%-71.5%$184.98MN/A0.00N/APositive NewsELDNEledon Pharmaceuticals1.5341 of 5 stars$3.11+1.0%$9.00+189.4%+38.5%$184.44MN/A-1.4810Positive NewsAnalyst RevisionCYBNCybin2.821 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050Analyst ForecastTILInstil Bio3.3787 of 5 stars$23.64-14.0%$119.00+403.4%+152.5%$180.37MN/A-1.97410Positive NewsGap DownHigh Trading VolumePBYIPuma Biotechnology4.2239 of 5 stars$3.54-1.1%$7.00+97.7%-1.5%$177.68M$230.50M4.60200Trending NewsVYGRVoyager Therapeutics3.9879 of 5 stars$3.04-5.0%$13.39+340.5%-61.0%$177.08M$80M-2.08100TLSATiziana Life Sciences1.3602 of 5 stars$1.53+1.3%N/A+80.5%$176.44MN/A0.008News CoveragePositive NewsIMABI-Mab2.8916 of 5 stars$2.09-2.8%$6.00+187.1%+34.8%$175.57M$3.89M0.00380Analyst ForecastGap Up Related Companies and Tools Related Companies NLTX Alternatives PROK Alternatives ALMS Alternatives ELDN Alternatives CYBN Alternatives TIL Alternatives PBYI Alternatives VYGR Alternatives TLSA Alternatives IMAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADVM Stock Alerts